Recurrent Glioblastomas

Background
The National Institutes of Health (NIH) is issuing a contract to conduct a clinical trial aimed at evaluating the efficacy and safety of LMP744, a novel indenoisoquinolone and CMYC/TOPOISOMERASE 1 inhibitor, in patients with recurrent glioblastoma.

The trial seeks to address the urgent need for effective therapies for this patient population by comparing progression-free and overall survival rates against historical controls. This study will also investigate molecular and metabolic responses to the drug, which will be critical for future phase III trials.

Work Details
The contractor shall provide all necessary services, qualified personnel, materials, equipment, and facilities to perform the following tasks: data collection, data abstraction, data identification, data validation, communication among the clinical team, and understanding of the clinical research protocol.

Clinical monitoring services will oversee research efforts away from direct patient care, ensuring accurate data abstraction, validation, and reporting. The contractor will monitor 40 enrolled patients continuously for safety assessments. Responsibilities include collaboration with the clinical team, attendance at clinical research meetings, identification of missing source documents, and requests for these documents from the research team.

Period of Performance
Base period from May 1, 2026 to April 30, 2027 with four additional option years.

Place of Performance
The work will be performed both onsite at the National Institutes of Health campus in Bethesda, Maryland and remotely.